COX-2 silencing enhances tamoxifen antitumor activity in breast cancer in vivo and in vitro

Du,Ye; Shi,Aiping; Han,Bing; Li,Sijie; Wu,Di; Jia,Hongyao; Zheng,Chao; Ren,Liqun; Fan,Zhimin

doi:10.3892/ijo.2014.2299

COX-2 silencing enhances tamoxifen antitumor activity in breast cancer in vivo and in vitro

Authors:
- Ye Du
- Aiping Shi
- Bing Han
- Sijie Li
- Di Wu
- Hongyao Jia
- Chao Zheng
- Liqun Ren
- Zhimin Fan
View Affiliations

Affiliations: Department of Breast Surgery, The First Hospital, Jilin University, Changchun 130021, Jilin, P.R. China, Department of Experimental Pharmacology and Toxicology, School of Pharmacy, Jilin University, Changchun 130021, Jilin, P.R. China
Published online on: February 12, 2014 https://doi.org/10.3892/ijo.2014.2299
Pages: 1385-1393

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Tamoxifen (Tam), a selective estrogen receptor modulator, is in wide clinical use for the treatment and prevention of breast cancer. However, extended TAM administration for breast cancer induces increased VEGF levels in patients, promoting new blood vessel formation and thereby limiting its efficacy and highlighting the need for improved therapeutic strategies. Cyclooxygenase-2 (COX-2) silencing via a replication-incompetent lentivirus (LV-COX-2) induce cancer apoptosis and suppresses VEGF gene expression. In this study, the effect of LV-COX-2 infection, either alone or in combination with TAM, was analyzed in a breast cell lines for suppressing VEGF expression and simultaneously reducing doses of TAM. Cell proliferation, apoptosis, angiogenesis, metastasis, cell cycle distribution, an receptor signaling were determined after LV-COX-2 combination with TAM treatment. In addition, tumor growth ability in nude mice was detected to define the combination treatment effect in tumorigenesis in vivo. It is found that LV-COX-2 combination with TAM treatment in breast cancer cell significantly suppressed the proliferation and metastasis, and induced tumor apoptosis in vitro, and tumor growth also was suppressed in vivo. In addition, we also found that LV-COX-2 combination with TAM treatment could inhibit angiogenesis and VEGF expression. Taken together, our experimental results indicate that LV-COX-2 combination with TAM has promising outcome in anti-metastatic and apoptotic studies. Furthermore, these results showed that LV-COX-2 combination with TAM is a potential drug candidate for treatment of breast tumors expressing high levels of VEGF.

View Figures

View References

1.	Jordan VC and O’Malley BW: Selective estrogen-receptor modulators and antihormonal resistance in breast cancer. J Clin Oncol. 25:5815–5824. 2007. View Article : Google Scholar : PubMed/NCBI
2.	Brauch H and Jordan VC: Targeting of tamoxifen to enhance antitumour action for the treatment and prevention of breast cancer: the ‘personalised’ approach? Eur J Cancer. 45:2274–2283. 2009.PubMed/NCBI
3.	Cuzick J, Sestak I, Pinder SE, et al: Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial. Lancet Oncol. 12:21–29. 2011. View Article : Google Scholar : PubMed/NCBI
4.	Roberts CG, Millar EK, O’Toole SA, et al: Identification of PUMA as an estrogen target gene that mediates the apoptotic response to tamoxifen in human breast cancer cells and predicts patient outcome and tamoxifen responsiveness in breast cancer. Oncogene. 30:3186–3197. 2011. View Article : Google Scholar : PubMed/NCBI
5.	Garvin S, Nilsson UW and Dabrosin C: Effects of oestradiol and tamoxifen on VEGF, soluble VEGFR-1, and VEGFR-2 in breast cancer and endothelial cells. Br J Cancer. 93:1005–1010. 2005. View Article : Google Scholar : PubMed/NCBI
6.	Qu Z, Van Ginkel S, Roy AM, et al: Vascular endothelial growth factor reduces tamoxifen efficacy and promotes metastatic colonization and desmoplasia in breast tumors. Cancer Res. 68:6232–6240. 2008. View Article : Google Scholar : PubMed/NCBI
7.	Majeti BK, Lee JH, Simmons BH and Shojaei F: VEGF is an important mediator of tumor angiogenesis in malignant lesions in a genetically engineered mouse model of lung adenocarcinoma. BMC Cancer. 13:2132013. View Article : Google Scholar : PubMed/NCBI
8.	Chen CT and Hung MC: Beyond anti-VEGF: dual-targeting antiangiogenic and antiproliferative therapy. Am J Transl Res. 5:393–403. 2013.PubMed/NCBI
9.	Breinig M, Schirmacher P and Kern MA: Cyclooxygenase-2 (COX-2) - a therapeutic target in liver cancer? Curr Pharm Des. 13:3305–3315. 2007. View Article : Google Scholar : PubMed/NCBI
10.	Stasinopoulos I, O’Brien DR, Wildes F, Glunde K and Bhujwalla ZM: Silencing of cyclooxygenase-2 inhibits metastasis and delays tumor onset of poorly differentiated metastatic breast cancer cells. Mol Cancer Res. 5:435–442. 2007. View Article : Google Scholar : PubMed/NCBI
11.	de Heer P, Sandel MH, Guertens G, et al: Celecoxib inhibits growth of tumors in a syngeneic rat liver metastases model for colorectal cancer. Cancer Chemother Pharmacol. 62:811–819. 2008.PubMed/NCBI
12.	Narayanan BA, Narayanan NK, Davis L and Nargi D: RNA interference-mediated cyclooxygenase-2 inhibition prevents prostate cancer cell growth and induces differentiation: modulation of neuronal protein synaptophysin, cyclin D1, and androgen receptor. Mol Cancer Ther. 5:1117–1125. 2006. View Article : Google Scholar
13.	Singh-Ranger G, Salhab M and Mokbel K: The role of cyclooxygenase-2 in breast cancer: review. Breast Cancer Res Treat. 109:189–198. 2008. View Article : Google Scholar : PubMed/NCBI
14.	Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT and De Bruijn EA: Vascular endothelial growth factor and angiogenesis. Pharmacol Rev. 56:549–580. 2004. View Article : Google Scholar : PubMed/NCBI
15.	Hasegawa K, Ichikawa W, Fujita T, et al: Expression of cyclooxygenase-2 (COX-2) mRNA in human colorectal adenomas. Eur J Cancer. 37:1469–1474. 2001. View Article : Google Scholar : PubMed/NCBI
16.	Kumar BN, Rajput S, Dey KK, et al: Celecoxib alleviates tamoxifen-instigated angiogenic effects by ROS-dependent VEGF/VEGFR2 autocrine signaling. BMC Cancer. 13:2732013. View Article : Google Scholar : PubMed/NCBI
17.	Lacroix I, Lapeyre-Mestre M, Bagheri H, et al: Nonsteroidal anti-inflammatory drug-induced liver injury: a case-control study in primary care. Fundam Clin Pharmacol. 18:201–206. 2004. View Article : Google Scholar : PubMed/NCBI
18.	Rudnick DA, Shikapwashya O, Blomenkamp K and Teckman JH: Indomethacin increases liver damage in a murine model of liver injury from alpha-1-antitrypsin deficiency. Hepatology. 44:976–982. 2006. View Article : Google Scholar : PubMed/NCBI
19.	Park JW, Park JE, Lee JA, Lee CW and Kim CM: Cyclooxygenase-2 (COX-2) is directly involved but not decisive in proliferation of human hepatocellular carcinoma cells. J Cancer Res Clin Oncol. 132:184–192. 2006. View Article : Google Scholar : PubMed/NCBI
20.	Wang R, Wang X, Lin F, Gao P, Dong K and Zhang HZ: shRNA-targeted cyclooxygenase (COX)-2 inhibits proliferation, reduces invasion and enhances chemosensitivity in laryngeal carcinoma cells. Mol Cell Biochem. 317:179–188. 2008. View Article : Google Scholar : PubMed/NCBI
21.	Lin T, Gu J, Zhang L, et al: Enhancing adenovirus-mediated gene transfer in vitro and in vivo by addition of protamine and hydrocortisone. J Gene Med. 5:868–875. 2003. View Article : Google Scholar : PubMed/NCBI
22.	Coleman JE, Huentelman MJ, Kasparov S, et al: Efficient large-scale production and concentration of HIV-1-based lentiviral vectors for use in vivo. Physiol Genomics. 12:221–228. 2003.PubMed/NCBI
23.	Deglon N, Tseng JL, Bensadoun JC, et al: Self-inactivating lentiviral vectors with enhanced transgene expression as potential gene transfer system in Parkinson’s disease. Hum Gene Ther. 11:179–190. 2000.PubMed/NCBI
24.	Tai MH, Weng CH, Mon DP, Hu CY and Wu MH: Ultraviolet C irradiation induces different expression of cyclooxygenase 2 in NIH 3T3 cells and A431 cells: the roles of COX-2 are different in various cell lines. Int J Mol Sci. 13:4351–4366. 2012. View Article : Google Scholar
25.	Frasor J, Danes JM, Komm B, Chang KC, Lyttle CR and Katzenellenbogen BS: Profiling of estrogen up- and down- regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology. 144:4562–4574. 2003. View Article : Google Scholar : PubMed/NCBI
26.	Renoir JM, Bouclier C, Seguin A, Marsaud V and Sola B: Antioestrogen-mediated cell cycle arrest and apoptosis induction in breast cancer and multiple myeloma cells. J Mol Endocrinol. 40:101–112. 2008. View Article : Google Scholar
27.	Zheng J and Yao Z: Effect of tamoxifen on apoptosis and drug resistance of breast cancer cells in vitro. Zhonghua Zhong Liu Za Zhi. 22:55–57. 2000.In Chinese.
28.	Thiantanawat A, Long BJ and Brodie AM: Signaling pathways of apoptosis activated by aromatase inhibitors and antiestrogens. Cancer Res. 63:8037–8050. 2003.
29.	Rajput S, Kumar BN, Sarkar S, et al: Targeted apoptotic effects of thymoquinone and tamoxifen on XIAP mediated Akt regulation in breast cancer. PLoS One. 8:e613422013. View Article : Google Scholar : PubMed/NCBI
30.	Blackwell KL, Haroon ZA, Shan S, et al: Tamoxifen inhibits angiogenesis in estrogen receptor-negative animal models. Clin Cancer Res. 6:4359–4364. 2000.PubMed/NCBI
31.	Marson LP, Kurian KM, Miller WR and Dixon JM: The effect of tamoxifen on breast tumour vascularity. Breast Cancer Res Treat. 66:9–15. 2001. View Article : Google Scholar : PubMed/NCBI
32.	Garvin S and Dabrosin C: Tamoxifen inhibits secretion of vascular endothelial growth factor in breast cancer in vivo. Cancer Res. 63:8742–8748. 2003.
33.	McNamara DA, Harmey J, Wang JH, Kay E, Walsh TN and Bouchier-Hayes DJ: Tamoxifen inhibits endothelial cell proliferation and attenuates VEGF-mediated angiogenesis and migration in vivo. Eur J Surg Oncol. 27:714–718. 2001. View Article : Google Scholar : PubMed/NCBI
34.	Ruohola JK, Valve EM, Karkkainen MJ, Joukov V, Alitalo K and Harkonen PL: Vascular endothelial growth factors are differentially regulated by steroid hormones and antiestrogens in breast cancer cells. Mol Cell Endocrinol. 149:29–40. 1999. View Article : Google Scholar : PubMed/NCBI
35.	Liu H, Xiao J, Yang Y, et al: COX-2 expression is correlated with VEGF-C, lymphangiogenesis and lymph node metastasis in human cervical cancer. Microvasc Res. 82:131–140. 2011. View Article : Google Scholar : PubMed/NCBI
36.	Mallen SR, Essex MN and Zhang R: Gastrointestinal tolerability of NSAIDs in elderly patients: a pooled analysis of 21 randomized clinical trials with celecoxib and nonselective NSAIDs. Curr Med Res Opin. 27:1359–1366. 2011. View Article : Google Scholar : PubMed/NCBI
37.	Rezende RM, Paiva-Lima P, Dos Reis WG, Camelo VM, Bakhle YS and de Francischi JN: Celecoxib induces tolerance in a model of peripheral inflammatory pain in rats. Neuropharmacology. 59:551–557. 2010. View Article : Google Scholar : PubMed/NCBI
38.	Du G, Yonekubo J, Zeng Y, Osisami M and Frohman MA: Design of expression vectors for RNA interference based on miRNAs and RNA splicing. FEBS J. 273:5421–5427. 2006. View Article : Google Scholar : PubMed/NCBI
39.	Stegmeier F, Hu G, Rickles RJ, Hannon GJ and Elledge SJ: A lentiviral microRNA-based system for single-copy polymerase II-regulated RNA interference in mammalian cells. Proc Natl Acad Sci USA. 102:13212–13217. 2005. View Article : Google Scholar
40.	Samakoglu S, Lisowski L, Budak-Alpdogan T, et al: A genetic strategy to treat sickle cell anemia by coregulating globin transgene expression and RNA interference. Nat Biotechnol. 24:89–94. 2006. View Article : Google Scholar : PubMed/NCBI
41.	Emdad L, Lebedeva IV, Su ZZ, et al: Combinatorial treatment of non-small-cell lung cancers with gefitinib and Ad.mda-7 enhances apoptosis-induction and reverses resistance to a single therapy. J Cell Physiol. 210:549–559. 2007. View Article : Google Scholar : PubMed/NCBI